NewLink Genetics Corp (NLNK)

15.44
0.06 0.39
NASDAQ : Health Care
Prev Close 15.50
Open 15.50
Day Low/High 14.93 / 15.60
52 Wk Low/High 9.23 / 56.16
Volume 342.71K
Avg Volume 730.90K
Exchange NASDAQ
Shares Outstanding 29.23M
Market Cap 441.60M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation - NLNK

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation - NLNK

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ:NLNK) into potential breaches of fiduciary duty...

NewLink Genetics Reports First Quarter 2017 Financial Results And Updates Clinical Trial Guidance

NewLink Genetics Reports First Quarter 2017 Financial Results And Updates Clinical Trial Guidance

Management to Host Conference Call Today at 8:30 a.m. ET

Six Stocks Spiking Up With Huge Volume

Six Stocks Spiking Up With Huge Volume

Here's a technical look at how to play six stocks trending higher with strong volume.

NEWLINK GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm

NEWLINK GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQGM:NLNK).

Interim Phase 2 Data Demonstrate Robust Response Rate With Indoximod In Combination With Keytruda® (pembrolizumab) For Patients With Advanced Melanoma At AACR Plenary

Interim Phase 2 Data Demonstrate Robust Response Rate With Indoximod In Combination With Keytruda® (pembrolizumab) For Patients With Advanced Melanoma At AACR Plenary

59% Objective Response Rate (ORR) and 80% Disease Control Rate (DCR) in 51 Patients with Non-ocular Melanoma

Strange: Bullish NLNK Analysts Actually See -7.33% Downside

Strange: Bullish NLNK Analysts Actually See -7.33% Downside

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with NewLink Genetics Corp . The average 12-month price target for NLNK — averaging the work of 6 analysts — reveals an average price target of $22.33/share.

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.

NLNK Crosses Above Average Analyst Target

NLNK Crosses Above Average Analyst Target

In recent trading, shares of NewLink Genetics Corp have crossed above the average analyst 12-month target price of $18.17, changing hands for $19.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

NewLink Genetics Announces Presentation Of Two Abstracts At AACR

NewLink Genetics Announces Presentation Of Two Abstracts At AACR

Interim Phase 2 Clinical Results of IDO Pathway Inhibitor, Indoximod Selected for an Oral Presentation During the Clinical Trial Plenary Session

NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results

NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results

Management to Host Conference Call and Webcast Today at 8:30 a.m. ET

Notable Monday Option Activity: NLNK, WTW, EBIX

Notable Monday Option Activity: NLNK, WTW, EBIX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NewLink Genetics Corp , where a total volume of 1,845 contracts has been traded thus far today, a contract volume which is representative of approximately 184,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 68.5% of NLNK's average daily trading volume over the past month, of 269,305 shares.

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ:NLNK) into potential breaches of fiduciary duty...

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Notable Monday Option Activity: NLNK, MSM, EXAS

Notable Monday Option Activity: NLNK, MSM, EXAS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NewLink Genetics Corp , where a total volume of 1,779 contracts has been traded thus far today, a contract volume which is representative of approximately 177,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 71.4% of NLNK's average daily trading volume over the past month, of 249,020 shares.

Stock Picks Are Hard to Find as Small-Caps Struggle

Stock Picks Are Hard to Find as Small-Caps Struggle

With poor breadth and money managers hiding in large-caps, I am being cautious, right now.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.

Shark Bites: We Knew Today Would Be Slow, but Come On…

Shark Bites: We Knew Today Would Be Slow, but Come On…

Don't force it; there's no energy.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Commit To Buy NewLink Genetics Corp At $8, Earn 16.2% Using Options

Commit To Buy NewLink Genetics Corp At $8, Earn 16.2% Using Options

Investors considering a purchase of NewLink Genetics Corp stock, but tentative about paying the going market price of $10.90/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.30.